Pralatrexate Patent Expiration
Pralatrexate is Used for treating patients with relapsed or refractory peripheral T-cell lymphoma. It was first introduced by Acrotech Biopharma Inc
Pralatrexate Patents
Given below is the list of patents protecting Pralatrexate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Folotyn | US7622470 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | May 31, 2025 | Acrotech Biopharma |
| Folotyn | US8299078 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | May 31, 2025 | Acrotech Biopharma |
| Folotyn | US6028071 | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul 16, 2022
(Expired) | Acrotech Biopharma |
Pralatrexate's Family Patents
Explore Our Curated Drug Screens
Pralatrexate Generic API Manufacturers
Several generic applications have been filed for Pralatrexate.
Given below is the list of companies who have filed for Pralatrexate generic, along with the locations of their manufacturing plants worldwide.
1. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Pralatrexate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG/ML (20MG/ML) | solution | Prescription | INTRAVENOUS | AP | Mar 10, 2025 |
| 40MG/2ML (20MG/ML) | solution | Prescription | INTRAVENOUS | AP | Mar 10, 2025 |